Atraverse Medical Acquired by Johnson & Johnson | Healthcare M&A Deal

Johnson & Johnson has acquired Atraverse Medical, a medical devices business in the cardiovascular space, for $2.38 billion. Atraverse Medical develops an FDA-cleared radiofrequency guidewire for atrial fibrillation ablation and left-heart access procedures, including treatment workflows for atrial septal defect. The Hotwire platform supports catheter-based electrophysiology use with reduced fluoroscopy in reported multicenter experience, strengthening Johnson & Johnson’s cardiovascular device portfolio. The Johnson & Johnson acquisitions are a strategic acquisition in healthcare M&A, expanding medtech capabilities in radiofrequency guidance for AFib ablation. Atraverse Medical began a limited launch after FDA clearance in 2024 and raised $12.5 million in 2024 and $29.4 million later, with the deal announced as an acquisition acquisition.